Teva Pharmaceutical Industries (TEVA) Debt to Equity: 2009-2025
Historic Debt to Equity for Teva Pharmaceutical Industries (TEVA) over the last 10 years, with Sep 2025 value amounting to $2.31.
- Teva Pharmaceutical Industries' Debt to Equity fell 22.16% to $2.31 in Q3 2025 from the same period last year, while for Sep 2025 it was $9.44, marking a year-over-year decrease of 21.88%. This contributed to the annual value of $3.31 for FY2024, which is 35.43% up from last year.
- Teva Pharmaceutical Industries' Debt to Equity amounted to $2.31 in Q3 2025, which was down 8.18% from $2.52 recorded in Q2 2025.
- In the past 5 years, Teva Pharmaceutical Industries' Debt to Equity ranged from a high of $3.31 in Q4 2024 and a low of $2.05 during Q4 2021.
- Moreover, its 3-year median value for Debt to Equity was $2.66 (2025), whereas its average is $2.68.
- As far as peak fluctuations go, Teva Pharmaceutical Industries' Debt to Equity spiked by 35.43% in 2024, and later fell by 22.16% in 2025.
- Teva Pharmaceutical Industries' Debt to Equity (Quarterly) stood at $2.05 in 2021, then increased by 20.38% to $2.47 in 2022, then dropped by 1.07% to $2.44 in 2023, then surged by 35.43% to $3.31 in 2024, then decreased by 22.16% to $2.31 in 2025.
- Its last three reported values are $2.31 in Q3 2025, $2.52 for Q2 2025, and $2.66 during Q1 2025.